ArchiveFebruary 2017

#PoliticalSpeak: the not so BigPharma Alternative – sorry we have let you down

We do not have enough hours, or energy, to reignite our BigPharma Alternative. #PoliticalSpeak #MSBlog Impact when you don’t expect, or deserve, to have one. I received the following email from a PhD researcher earlier this week: Dear Prof. Giovannoni, Your article about repurposing in ‘Multiple Sclerosis and Related Disorders’ has caught my attention. I am a ….. researcher at the...

#ResearchSpeak & #ThinkHand: MS outcomes – are we closer to the holy grail

Are we closer to doing defining a new battery of outcome measures for progressive MS? #ThinkHand #ResearchSpeak #MSBlog Those of you who follow this blog will realise that we are gradually developing an online suite of apps to help you self-monitor your disease. Why? To empower you to ask the right questions about your prognosis and treatments. It is clear that when DMTs for progressive MS are...

No publication without reproduction

Mogil JS & Macleod MRNo publication without confirmation This says “Concern over the reliability of published biomedical results grows unabated. Frustration with this ‘reproducibility crisis’ is felt by everyone pursuing new disease treatments: from clinicians and would-be drug developers who want solid foundations on which animal studies are based”. ...

HSCT activity in Progressive MS

Paolo A. Muraro, et al.Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. JAMA Neurol 2017 Question:  What are the long-term outcomes after autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis? Findings:  In this multicenter cohort study of 281 patients with predominantly progressive forms of multiple...

#NeuroSpeak & #ClinicSpeak: treating PML-related IRIS

A new treatment for PML-related IRIS based on hard science and anecdote #NeuroSpeak #ClinicSpeak #MSBlog Substituting one disease for another. A large number of you argue that by treating MS, a disabling disease, with immunosuppressive therapies we simply create another ticking time bomb and swap one disease, MS, for another disease, immunosuppression. The difference between these two diseases is...

Guest Post MSBaseGold: Comparisons of DMT

Today we are delighted to have another Guest post from Tomas Kalincik from University of Melbourne, Australia, please see his Biography on his previous post. Kalincik et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol. 2017 Feb 10. pii: S1474-4422(17)30007-8...

Real world data on efficacy or #alternativefact

Neurol Ther. 2017 Feb 16. doi: 10.1007/s40120-017-0064-x. [Epub ahead of print] Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database. Boster A, Nicholas J, Wu N, Yeh WS, Fay M, Edwards M, Huang MY, Lee A. Abstract INTRODUCTION: Limited data are available on the real-world effectiveness of...

#OffLabel & #ClinicSpeak: nabilone instead of street cannabis

Off label Nabilone is a treatment option for MS-related spasticity #OffLabel #ClinicSpeak #MSBlog I grew up in apartheid South Africa and recall the sweet smell of ‘dagga’ (SA street lingo for cannabis), that wafted from the workers, or gardeners, quarters at my primary school. The workers, who were all black at that time, generally used cannabis in large amounts to survive the...

The SPMS trial that never was.

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.Brochet B, Deloire MS, Perez P, Loock T, Baschet L, Debouverie M, Pittion S, Ouallet JC, Clavelou P, de Sèze J, Collongues N, Vermersch P, Zéphir H, Castelnovo G, Labauge P, Lebrun C, Cohen M, Ruet A; PROMESS study investigators..PLoS One. 2017 Jan 3;12(1):e0168834...

#ResearchSpeak: when best practice clinical guidelines our out of date

Is your neurologist a sheep or a wolf, a herder or an independent thinker? #ResearchSpeak #MSBlog The following study looks at decision-making by neurologists in relation to a simple case scenario. The researchers come to the conclusion that neurologists display herd behaviour, i.e. they follow the crowd rather deciding independently. The study is based on a simple case scenario of a 40-year-old...

Translate

Categories

Recent Posts

Recent Comments

Archives